2. Introduction
Diagnosis
Brief Pathology
Treatment and Prognosis
Other symptoms/complications
Phases
Other Neurodegenerative diseases
Quiz
3. PD is a movement disorder
› Prevalence: 100 – 180/100,000 in UK
› Incidence: 4 – 20/100,000 in UK
› M > F
Parkinsonism – syndrome of:
› Bradykinesia (poverty of movement)
› Resting tremor
› Rigidity
› Varying degrees of postural instability
4. Asymmetrical onset
Slow progression
Good response to L-dopa therapy
N.B. only 60% develop tremor!
5. Clinical – structural imaging normal
Helpful signs:
› Micrographia
› Loss of arm swing
› Facial hypomimia (mask like)
› Cogwheel stiffness
› 4 – 7 Hz resting tremor
6. Symmetrical onset
Early falling
Early cognitive impairment
Prominent autonomic disturbance (sphincter
involvement)
Pyramidal tract or cerebellar signs
Classic MCQ trick innit!
7. Loss of dopamine producing cells in the
substantia nigra
Also involves Serotonin, Acetylcholine and
Noradrenaline neurotransmitters
Lewy bodies (intraneuronal protein inclusions)
Most not genetic unless present < 30
› Parkin gene
8. PD is progressive
Pharmacological intervention changes as the
condition advances
No universal first line treatment
› Patient choice and all that jazz!
9. Drug Group Examples Side Effects
Dopamine
Agonists
Bromocriptine
Pergolide
Cabergoline
Apomorphine
Pramipexole
Ropinorole
• Neuropsychiatric
• Ergots fibrosis
• Give Domperidone with
Apomorphine
• Hypotensive reactions
• SOOS and day sleepiness
Levodopa
Give with dopa-
decarboxylase
inhibitors
Co-careldopa (Sinemet)
(Ldopa + Carbidopa)
Co-benyldopa (Madopar)
(Ldopa + Benserazide)
• Response fluctuations ‘on-
off’
• Dyskinesias
• Anticholinergic
• Post. Hypotension
• Psychiatric
• N,V
MAOIs Selegiline
• Postural Hypotension
• Anticholinergic type
• Sleep disorders
• Confusion
• Nausea
10. Drug Group Example Side Effects
COMT Inhibitors
- Prevent peripheral
breakdown of Ldopa
- Can be used 1st line
according to NICE
Entacapone
Tolcapone
N,V
Diarrhoea, Constipation
Abdo pain
Urine goes red-brown
Dry mouth
Confusion
Insomnia etc
Amantidine
- Weak dopamine
agonist
- Antiviral
Amantadine
Hydrochloride
Anorexia
Nervousness
Insomnia
Reduced concentration
12. Diagnosis Refer to Specialists
› Medication may not be necessary
Maintenance Medication prescribed
› Medications increase over time, monitor
› Essentially stable
Complex Motor fluctuations: on-off/dyskinesia
› Other meds added: Amantadine, ? agonist, ? add anti-psychotics
› Provide information support and advice, monitor regularly, prevent
psychotic symptoms! Avoid hospital admission
Palliative
› Medications less effective, may be no observable benefit. ?PEG – early.
› Symptom control, specialist services, end of life choices
13. Parkinson Plus Syndromes:
› Multiple System Atrophy
› Progressive Supranuclear Palsy
› Dementia with Lewy Bodies
› Corticobasal degeneration
Drug induced Parkinsonism:
› Neuroleptics
› Antiemetics – which one?
› Lithium
Vascular Parkinsonism :
› Marked sparing of upper limbs
› Check vascular RF
14. Parksinson’s Disease:
Is usually inherited
Presents with early falling
Should show a good response to L-dopa
Can be treated with Deep Brain Stimulation
Usually presents with symmetrical onset
Constipation is a symptom
15. NICE guidelines
COMP2 presentations from blackboard…
grr!
Medicine At a Glance.
www.wikipedia.org
www.meducation.net
Editor's Notes
Serotonin – mood and behaviour
Acetylcholine – cognition and memory
Noradrenalin – Autonomic function - BP
Ergot derived dopamine agonists have been associated with pericardial, pulmonary and retroperitoneal fibrotic reactions. Before starting treatment it may be appropriate to measure ESR and serum creatinine and. Monitor for dyspnoea, persistent cough or chest pain, cardiac failure and abdominal tenderness.
Start dose small and increase slowly. Do not stop abruptly
Giving ldopa with decarboxylase inhibitors limits peripheral conversion to dopamine which would cause nausea and cardiovascular side effects. Avoud abrupt withdrawal because neuroleptic syndrome and rhabdomyolysis can occur.
COMT = Catechol O methyltransferase inhibitors. Use as adjunct to Ldopa in PD and end of dose motor fluctuations.